Find Sincalide manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF DossiersDRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

34 RELATED EXCIPIENT COMPANIES

73EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 25126-32-3, Cck-8, Kinevac, Sq 19844, Cck c-terminal octapeptide, Cholecystokinin c-terminal octapeptide
Molecular Formula
C49H62N10O16S3
Molecular Weight
1143.3  g/mol
InChI Key
IZTQOLKUZKXIRV-YRVFCXMDSA-N
FDA UNII
M03GIQ7Z6P

Sincalide
An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.
Sincalide is a Cholecystokinin Analog.
1 2D Structure

Sincalide

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic acid
2.1.2 InChI
InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1
2.1.3 InChI Key
IZTQOLKUZKXIRV-YRVFCXMDSA-N
2.1.4 Canonical SMILES
CSCCC(C(=O)NCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(CC3=CC=CC=C3)C(=O)N)NC(=O)C(CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)C(CC(=O)O)N
2.1.5 Isomeric SMILES
CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)N
2.2 Other Identifiers
2.2.1 UNII
M03GIQ7Z6P
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Cck-8

2. Cck-op

3. Cholecystokinin Octapeptide

4. Cholecystokinin Pancreozymin C Terminal Octapeptide

5. Cholecystokinin Pancreozymin C-terminal Octapeptide

6. H-asp-tyr(so3h)-met-gly-trp-met-asp-phe-nh2

7. Kinevac

8. Op-cck

9. Sq 19,844

10. Sq 19844

11. Sq-19,844

12. Sq-19844

13. Sq19,844

14. Sq19844

15. Syncalide

2.3.2 Depositor-Supplied Synonyms

1. 25126-32-3

2. Cck-8

3. Kinevac

4. Sq 19844

5. Cck C-terminal Octapeptide

6. Cholecystokinin C-terminal Octapeptide

7. Sq-19844

8. Chembl1121

9. M03giq7z6p

10. Cholecystokinin Octapeptide

11. Caerulein, 1-de(5-oxo-l-proline)-2-de-l-glutamine-5-l-methionine-

12. H-asp-tyr(so3h)-met-gly-trp-met-asp-phe-nh2

13. Cholecystokinin 8

14. Dsstox_cid_28543

15. Dsstox_rid_82815

16. Dsstox_gsid_48617

17. L-aspartyl-l-tyrosyl-l-methionylglycyl-l-tryptophyl-l-methionyl-l-aspartylphenyl-l-alaninamide Hydrogen Sulfate (ester)

18. Sincalidum

19. Sincalida

20. Syncalide

21. (3s,6s,9s,15s,18s,21s)-9-((1h-indol-3-yl)methyl)-21-amino-3-(((s)-1-amino-1-oxo-3-phenylpropan-2-yl)carbamoyl)-6,15-bis(2-(methylthio)ethyl)-5,8,11,14,17,20-hexaoxo-18-(4-(sulfooxy)benzyl)-4,7,10,13,16,19-hexaazatricosanedioic Acid

22. Cas-25126-32-3

23. Human Cck-8

24. Cck-8 (sulphated)

25. Asp-tyr(so3h)-met-gly-trp-met-asp-phe-nh2

26. Sincalidum [inn-latin]

27. Sincalida [inn-spanish]

28. Unii-m03giq7z6p

29. Pancreozymin

30. Sincalide [usan:usp:inn:ban]

31. Ncgc00183278-01

32. Ncgc00183363-01

33. 3-10-caerulein, 5-l-methionine-

34. Einecs 246-639-0

35. Kinevac (tn)

36. Mfcd00079849

37. Sq19844

38. Sincalide [inn]

39. Sincalide [mi]

40. Sincalide (usan/inn)

41. Sincalide [usan]

42. Sincalide [vandf]

43. Cholecystokinin-pancreozymin

44. Sincalide [mart.]

45. Sincalide [who-dd]

46. Cholecystokinin Fragment 26-33 Amide (sulphated)

47. Gtpl864

48. Schembl122365

49. (tyr[so3h]27)cholecystokinin Fragment 26-33 Amide

50. Cck-8(so3)

51. Sincalide [orange Book]

52. Dtxsid7048617

53. Sincalide [usp Impurity]

54. Bdbm21147

55. Chebi:135946

56. (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic Acid

57. [125i]cck-8

58. 1-de(5-oxo-l-proline)-2-de-l-glutamine-5-l-methioninecaerulein

59. Hy-p0093

60. Sq19844cholecystokinin Octapeptide

61. Tox21_112955

62. Tox21_113481

63. Cholecystokinin Octapeptide, Sulfated

64. Coralynechloridehydrate,98+%

65. Akos016340423

66. Cs-5963

67. Db09142

68. Hs-2026

69. Ncgc00167273-01

70. L-alpha-aspartyl-o-sulfo-l-tyrosyl-l-methionylglycyl-l-tryptophyl-l-methionyl-l-alpha-aspartyl-l-phenylalaninamide

71. Cholecystokinin, Cck Octapeptide (26-33)

72. D05845

73. E78048

74. Asp26-tyr(so3h)-met-gly-trp-met-asp-phenh2

75. 126s323

76. Cholecystokinin C-terminal Octapeptide [mi]

77. Cholecystokinin Octapeptide (sulfated) Ammonium Salt

78. Q7521885

79. (3s)-3-[(2s)-2-[(2s)-2-{2-[(2s)-2-[(2s)-2-[(3s)-3-amino-3-formamidopropanoic Acid]-3-[4-(sulfooxy)phenyl]propanamido]-4-(methylsulfanyl)butanamido]acetamido}-3-(1h-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-{[(1s)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic Acid

80. (3s)-3-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-4-hydroxy-4-oxobutanoyl]amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic Acid

81. (3s,6s,9s,15s,18s,21s)-9-((1h-indol-3-yl)methyl)-21-amino-3-(((s)-1-amino-1-oxo-3-phenylpropan-2-yl)carbamoyl)-6,15-bis(2-(methylthio)ethyl)-5,8,11,14,17,20-hexaoxo-18-(4-(sulfooxy)benzyl)-4,7,10,13,16,19-hexaazatricosane-1,23-dioic Acid

82. (3s,6s,9s,15s,18s,21s)-9-((1h-indol-3-yl)methyl)-21-amino-3-((s)-1-amino-1-oxo-3-phenylpropan-2-ylcarbamoyl)-6,15-bis(2-(methylthio)ethyl)-5,8,11,14,17,20-hexaoxo-18-(4-(sulfooxy)benzyl)-4,7,10,13,16,19-hexaazatricosane-1,23-dioic Acid

83. L-.alpha.-aspartyl-o-sulfo-l-tyrosyl-l-methionylglycyl-l-tryptophyl-l-methionyl-l-.alpha.-aspartyl-l-phenylalaninamide

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 1143.3 g/mol
Molecular Formula C49H62N10O16S3
XLogP3-2.6
Hydrogen Bond Donor Count13
Hydrogen Bond Acceptor Count19
Rotatable Bond Count33
Exact Mass1142.35073945 g/mol
Monoisotopic Mass1142.35073945 g/mol
Topological Polar Surface Area486 Ų
Heavy Atom Count78
Formal Charge0
Complexity2180
Isotope Atom Count0
Defined Atom Stereocenter Count7
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

As the product Kinevac (FDA), sincalide is used for the following indications: 1) to stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; (2) to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; (3) to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.


FDA Label


5 Pharmacology and Biochemistry
5.1 FDA Pharmacological Classification
5.1.1 Active Moiety
SINCALIDE
5.1.2 FDA UNII
M03GIQ7Z6P
5.1.3 Pharmacological Classes
Cholecystokinin [CS]; Cholecystokinin Analog [EPC]
5.2 ATC Code

V - Various

V04 - Diagnostic agents

V04C - Other diagnostic agents

V04CC - Tests for bile duct patency

V04CC03 - Sincalide


5.3 Absorption, Distribution and Excretion

Absorption

The intravenous (bolus) administration of sincalide causes a prompt contraction of the gallbladder that becomes maximal in 5 to 15 minutes, as compared with the stimulus of a fatty meal which causes a progressive contraction that becomes maximal after approximately 40 minutes.


5.4 Mechanism of Action

When injected intravenously, sincalide produces a substantial reduction in gallbladder size by causing this organ to contract. The evacuation of bile that results is similar to that which occurs physiologically in response to endogenous cholecystokinin. Like cholecystokinin, sincalide stimulates pancreatic secretion; concurrent administration with secretin increases both the volume of pancreatic secretion and the output of bicarbonate and protein (enzymes) by the gland. This combined effect of secretin and sincalide permits the assessment of specific pancreatic function through measurement and analysis of the duodenal aspirate.


DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - POWDER;INTRAVENOUS - 0.005MG/VIAL

USFDA APPLICATION NUMBER - 17697

read-more

DOSAGE - POWDER;INTRAVENOUS - 0.005MG/VIAL

USFDA APPLICATION NUMBER - 210850

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Direct Compression

read-more
read-more

Taste Masking

read-more
read-more

Parenteral

read-more
read-more

Solubilizers

read-more
read-more

Topical

read-more
read-more

Granulation

read-more
read-more

Co-Processed Excipients

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Emulsifying Agents

read-more
read-more

API Stability Enhancers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty